Autism spectrum disorder affects millions of people across the globe, and there is a real need for new medications that can help with some of the social and behavioral challenges associated with it. A compound found in hemp and cannabis, CBDV (cannabidivarin), has shown promise in preclinical animal models of autism spectrum disorder and is being studied in a clinical trial designed to enroll 100 children and adolescents.
The main areas being investigated include sociability, motor coordination, short-term memory, irritability and repetitive movements. CBDV is also being examined for seizures, muscular dystrophy and attention-deficit/hyperactivity disorder (ADHD). This article explains what CBDV is and reviews research on CBDV, CBD and autism.
What Is CBDV?
Hemp and cannabis plants contain more than 100 cannabinoids. These active compounds interact with the human endocannabinoid system in different ways. The best-known cannabinoids are non-intoxicating CBD (cannabidiol) and intoxicating THC (tetrahydrocannabinol). Dozens of others are called “rare” or “minor” cannabinoids because they occur in much smaller quantities.
CBDV is a rare cannabinoid and a close chemical relative of CBD. Like CBD, it is not known to produce the high associated with THC.
Scientists are studying CBDV for seizures, inflammation and several neurological and neurodevelopmental conditions. Early autism-related research suggests that it may influence brain signaling and behaviors involving sociability, memory, activity levels and repetition. Whether these effects translate into meaningful benefits for autistic people remains the subject of ongoing research.
CBD, THC, CBDV and other cannabinoids interact with biological pathways involved in memory, emotional processing, sleep, pain, hunger and other functions.
Autism Symptoms and Prevalence
Autism spectrum disorder (ASD) refers to a wide range of neurodevelopmental differences involving social communication, behavior and sensory processing. Some autistic people also experience anxiety, irritability, impulsivity, sleep disruption or repetitive behaviors. Signs of autism usually appear in early childhood. Various therapies and forms of support can help with particular challenges, but autism is a lifelong condition rather than an illness with a cure.
It is important to distinguish between trying to “cure” autism and helping autistic people with symptoms that cause distress or interfere with daily life. Autism is a form of neurodiversity, and autistic people are not broken or in need of being made “normal.” The goal of treatment research should be to alleviate difficult associated symptoms—such as severe irritability, anxiety, sleep disruption, seizures or self-injury—when an autistic person or their family wants support. Any potential benefit should ultimately be measured by improvements in comfort, wellbeing, autonomy and quality of life, not by how closely someone appears to conform to non-autistic behavior.
The FDA has approved two antipsychotic medications for treating irritability associated with autism spectrum disorder. These medications can be helpful for some people but can also cause significant side effects. Antidepressants, anti-anxiety medications and other drugs may be prescribed for co-occurring symptoms or conditions.
In 2025, the Centers for Disease Control and Prevention reported that approximately one in 31 eight-year-old children in the United States had been identified with autism spectrum disorder. Northern Ireland has reported autism diagnoses among more than one in 25 school-age children.
With so many children, adults, families and caregivers affected by autism, there is a clear need for well-designed research into additional treatment options for symptoms that interfere with health or daily life.
Clinical Trial of CBDV for Autism Spectrum Disorder
CBDV has shown potential in preclinical research involving repetitive behavior, irritability, sociability and related measures. It is now being examined for safety and efficacy in autistic children.
ClinicalTrials.gov study NCT03202303 is a randomized, double-blind, placebo-controlled Phase 2 trial designed to enroll 100 autistic children and adolescents between 5 and 18 years old. The study’s primary aim is to determine CBDV’s effect on irritability. Researchers are also measuring repetitive behavior, social functioning, caregiver strain, quality of life, safety and tolerability.
The registry currently lists the study as recruiting and does not include results. The trial’s existence therefore shows that CBDV has advanced into human efficacy research, but not yet that it has been proven to help autistic children.
Animal and Human Studies on CBDV for Autism
The pediatric clinical trial follows encouraging findings from preclinical experiments and small human brain-imaging studies:
- A 2019 study of CBDV in a rat model relevant to autism found changes in sociability, short-term memory, repetitive self-grooming and hyperactivity. At some doses and treatment stages, CBDV also restored alterations in hippocampal endocannabinoid signaling, inflammatory markers and microglial activity. The researchers described the findings as preclinical evidence supporting further study of CBDV. Because the experiment used an animal model and injected purified CBDV, it cannot establish how commercially available CBDV will affect people.
- A 2019 experiment examined CBDV’s effects on brain excitation and inhibition in adults with and without autism spectrum disorder. Researchers found that a single 600 mg dose of CBDV altered glutamate-related signaling in parts of the brain. They suggested that future studies examine whether these biological effects are accompanied by changes in behavior or symptoms.
- Researchers found that CBDV may influence atypical brain connectivity in a small 2021 randomized pilot study. After a single 600 mg dose, some patterns of hyperconnectivity measured in autistic adult men shifted toward levels observed in the non-autistic comparison group. The study did not determine whether those brain changes produced clinical or behavioral improvements.
- CBDV has also been studied in mouse models of Rett syndrome, a separate genetic neurodevelopmental disorder that can share some features with autism. In one 2018 study, CBDV improved sociability and general health, partly improved motor coordination and restored brain weight in mice.
- In a separate 2019 Rett syndrome study, CBDV rescued recognition-memory deficits and delayed the appearance of some neurological and motor problems in mice.
- Clinical study NCT05219370 was designed to examine cannabis oils containing varying ratios of CBD, CBDV, CBG and THC in adults with ADHD.
- CBDV has also been investigated alongside CBD and THCV in preclinical muscular-dystrophy research. This research is not evidence about autism, but it contributes to scientists’ understanding of CBDV’s broader biological activity.
CBDV Oil Availability
Although CBDV is similar to CBD, it naturally occurs in much smaller quantities in hemp and cannabis plants. That makes it more difficult and expensive to isolate and manufacture into a finished product. CBDV products are consequently much less common than CBD products; one available example is CBDV oil from Rare Cannabinoid Company.
Anyone considering using CBDV or other hemp-derived cannabinoids—especially alongside medications—should first speak with a qualified healthcare professional.
CBDV vs. CBD Oil for Autism
In addition to CBDV, multiple studies have examined CBD or CBD-rich cannabis preparations in autistic people. CBD and CBDV are different cannabinoids, however, and evidence about one cannot automatically be applied to the other.
- In a large observational study of medical cannabis use, parents and caregivers reported improvements in areas such as behavior, anxiety and communication for some autistic participants. The products contained CBD and THC in varying proportions, and the study was not placebo-controlled.
- A 2019 retrospective study reported parent-observed improvements in self-injury or rage attacks, hyperactivity, sleep problems and anxiety among portions of a group of autistic children receiving CBD-rich cannabis.
- A 2019 observational study involving 18 participants reported improvements of at least 30% in one or more assessed areas among 14 of the 15 participants who completed treatment.
- A randomized controlled study involving 60 children reported improvements in social interaction, anxiety and psychomotor agitation with a CBD-rich cannabis extract.
- In a 2025 randomized crossover study of purified CBD in autistic boys with severe behavior problems, blinded clinicians observed improvement in some participants, particularly involving aggression, hyperactivity and communication. However, the study found no statistically significant CBD-versus-placebo differences on its broad primary behavioral measures, and a substantial placebo response was recorded.
These studies have helped build interest in cannabinoids and autism research. Nevertheless, differences in product composition, study design, participant characteristics and outcome measures make it difficult to draw a single conclusion from them.
How to Evaluate CBDV Products
Because CBDV is scarce and generally more expensive than CBD, consumers should confirm that a product actually contains a meaningful amount of CBDV rather than relying on the front label alone.
Look for a batch-specific certificate of analysis from an independent laboratory. The report should test the finished product—not merely a raw ingredient—and confirm its CBDV content as well as screening for relevant contaminants. The cannabinoid quantities on the laboratory report should be consistent with the product label.
It is also useful to look for clear labeling, accessible laboratory reports and manufacturing in a facility that follows current Good Manufacturing Practices. These checks cannot establish that a product will produce a particular health effect, but they can help confirm that the contents match the label.
The Outlook for CBDV and Autism Research
CBDV has progressed from a little-known cannabinoid to a subject of animal research, small controlled human brain studies and a registered pediatric clinical trial. The animal findings involving sociability, memory, repetitive behavior and activity levels are encouraging. The adult studies also show that CBDV can reach and influence brain systems relevant to autism research.
The essential question is whether those biological and preclinical findings will translate into meaningful improvements for autistic children or adults. Results from the pediatric trial and additional longer-term human research will be needed to answer that question.
As restrictions on cannabis and hemp research continue to ease, scientists should be better able to conduct robust clinical trials of CBDV, CBD and other cannabinoids for autism-related symptoms and other potential health applications.
This article is for informational purposes only and is not medical advice. CBDV has not been approved by the U.S. Food and Drug Administration to diagnose, treat, cure or prevent autism. Consult a qualified healthcare professional before consuming cannabinoids.
As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN neither agrees nor disagrees with any of the materials posted. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement.
Opinion Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy of WHN. Any content provided by guest authors is of their own opinion and is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything else. The Food and Drug Administration has not evaluated these statements.
